US 11,951,172 B2
Therapeutic molecules that bind to LAG3 and PD1
Carolyn Edwards, Cambridge (GB); Angelica Sette, Cambridge (GB); Isabelle Osuch, Cambridge (GB); Yumin Teng, Cambridge (GB); James Legg, Cambridge (GB); and David Escors Murugarren, Pamplona (ES)
Assigned to CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
Appl. No. 16/969,905
Filed by CRESCENDO BIOLOGICS LIMITED, Cambridge (GB)
PCT Filed Feb. 18, 2019, PCT No. PCT/GB2019/050425
§ 371(c)(1), (2) Date Aug. 13, 2020,
PCT Pub. No. WO2019/158942, PCT Pub. Date Aug. 22, 2019.
Claims priority of application No. 1802573 (GB), filed on Feb. 16, 2018.
Prior Publication US 2021/0015937 A1, Jan. 21, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 47/68 (2017.01); C07K 16/18 (2006.01); C07K 16/28 (2006.01); C12N 15/10 (2006.01); C07K 16/46 (2006.01)
CPC A61K 47/6801 (2017.08) [A61K 39/3955 (2013.01); C07K 16/2818 (2013.01); C12N 15/10 (2013.01); C07K 16/28 (2013.01); C07K 16/2803 (2013.01); C07K 16/46 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01); C07K 2317/626 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01)] 24 Claims
OG exemplary drawing
 
1. An isolated human heavy chain variable domain (VH) single domain antibody that binds to human LAG-3 comprising a CDR1 sequence as shown in SEQ ID NO: 1 or a CDR1 sequence as shown in SEQ ID NO: 1 comprising a Y to F substitution in CDR1 at position 32 of the sequence as shown in SEQ ID NO: 4, a CDR2 sequence as shown in SEQ ID NO: 2 or a CDR2 sequence as shown in SEQ ID NO: 2 comprising a N to S substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, a S to T substitution in CDR2 at position 58 of the sequence as shown in SEQ ID NO: 4, a N to I substitution in CDR2 at position 54 of the sequence as shown in SEQ ID NO: 4, a G to S substitution in CDR2 at position 55 of the sequence as shown in SEQ ID NO: 4, a G to D substitution in CDR2 at position 56 of the sequence as shown in SEQ ID NO: 4, a N to I substitution in CDR2 at position 57 of the sequence as shown in SEQ ID NO: 4, or a G to A substitution in CDR2 at position 59 of the sequence as shown in SEQ ID NO: 4, and a CDR3 sequence as shown in SEQ ID NO: 3 or a CDR3 sequence as shown in SEQ ID NO: 3 comprising a S to V substitution in CDR3 at position 106 of the sequence as shown in SEQ ID NO: 4, a S to A substitution in CDR3 at position 108 of the sequence as shown in SEQ ID NO: 4, or a A to T substitution in CDR3 at position 107 of the sequence as shown in SEQ ID NO: 4, or a CDR1 sequence as shown in SEQ ID NO: 5, a CDR2 sequence as shown in SEQ ID NO: 6, and a CDR3 sequence as shown in SEQ ID NO: 7.